Instil Bio, Inc.

TILSEC EDGAR

Biological Products, (No Diagnostic Substances)(NY)CIK: 1789769

Concept	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	$138.0K
Research and Development Expense	—	$141.1M	$107.3M	$19.4M
Operating Expenses	$159.2M	$226.5M	$155.6M	$33.8M
Operating Income (Loss)	-$159.2M	-$226.5M	-$155.6M	-$33.6M
Interest Expense	—	$1.9M	$0.00	—
Nonoperating Income (Expense)	-$575.0K	-$564.0K	-$1.3M	-$3.9M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$156.1M	-$225.3M	-$156.8M	-$37.6M
Income Tax Expense (Benefit)	—	-$2.1M	$39.0K	$151.0K
Net Income (Loss) Attributable to Parent	-$156.1M	-$223.2M	-$156.8M	-$37.7M
Earnings Per Share, Basic

Concept	FY2024	FY2023	FY2022	FY2021
Assets	$325.6M	$482.1M	$610.0M	$319.0M
Assets, Current	$160.8M	$269.4M	$464.0M	$246.1M
Cash and Cash Equivalents, at Carrying Value	$9.2M	$43.7M	$37.6M	$241.7M
Liabilities	$99.8M	$118.5M	$54.8M	$26.6M
Liabilities, Current	$10.6M	$32.8M	$41.4M	$13.3M
Accounts Payable, Current	$1.2M	$2.4M	$5.6M	$3.5M
Stockholders' Equity Attributable to Parent	$363.6M	$555.2M	-$39.6M	-$6.9M
Common Stock, Shares, Outstanding	$6.5M	$6.5M	$129.0M	$20.6M

Concept	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$82.0M	-$180.2M	-$122.1M	-$29.6M
Net Cash Provided by (Used in) Investing Activities	$41.1M	$114.5M	-$474.4M	-$51.1M
Net Cash Provided by (Used in) Financing Activities	$8.1M	$71.9M	$393.2M	$313.0M
Payments to Acquire Property, Plant, and Equipment	$20.7M	$84.6M	$57.8M	$37.6M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)